Wellington Management Group LLP Has $115.15 Million Holdings in Stoke Therapeutics, Inc. $STOK

Wellington Management Group LLP increased its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 13.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,519,301 shares of the company’s stock after acquiring an additional 423,601 shares during the quarter. Wellington Management Group LLP owned about 0.05% of Stoke Therapeutics worth $115,152,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of STOK. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the fourth quarter valued at about $26,000. Quantbot Technologies LP bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $34,000. KBC Group NV acquired a new position in shares of Stoke Therapeutics during the first quarter worth approximately $36,000. Harbour Investments Inc. lifted its holdings in shares of Stoke Therapeutics by 312.9% during the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on STOK shares. JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They issued an “overweight” rating and a $40.00 price objective on the stock. BTIG Research reissued a “buy” rating and issued a $39.00 price target on shares of Stoke Therapeutics in a report on Monday, May 11th. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, Canaccord Genuity Group cut their price objective on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $44.25.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $30.89 on Wednesday. The stock has a fifty day moving average price of $31.22 and a two-hundred day moving average price of $32.24. Stoke Therapeutics, Inc. has a 52-week low of $18.80 and a 52-week high of $40.22. The firm has a market capitalization of $1.99 billion, a P/E ratio of -9.25 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The firm had revenue of $9.32 million during the quarter, compared to analyst estimates of $4.89 million. On average, equities research analysts predict that Stoke Therapeutics, Inc. will post -3.52 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $402,521.01. Following the completion of the transaction, the director directly owned 124,557 shares of the company’s stock, valued at $3,989,560.71. This trade represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Jonathan Allan sold 2,861 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total transaction of $91,637.83. Following the completion of the transaction, the general counsel owned 21,225 shares in the company, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 28,828 shares of company stock valued at $898,874 in the last ninety days. Insiders own 9.60% of the company’s stock.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.